Cardiol Therapeutics Cash Per Share vs. Gross Profit

Based on Cardiol Therapeutics' profitability indicators, Cardiol Therapeutics Class may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Cardiol Therapeutics' ability to earn profits and add value for shareholders.
For Cardiol Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cardiol Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cardiol Therapeutics Class utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cardiol Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cardiol Therapeutics Class over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Cardiol Therapeutics Gross Profit vs. Cash Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Cardiol Therapeutics's current stock value. Our valuation model uses many indicators to compare Cardiol Therapeutics value to that of its competitors to determine the firm's financial worth.
Cardiol Therapeutics Class is rated third in cash per share category among its peers. It is rated fourth in gross profit category among its peers fabricating about  69,088  of Gross Profit per Cash Per Share. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cardiol Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Cardiol Gross Profit vs. Cash Per Share

Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Cardiol Therapeutics

Cash Per Share

 = 

Total Cash

Average Shares

 = 
1.14 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Cardiol Therapeutics

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
78.76 K
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Cardiol Gross Profit Comparison

Cardiol Therapeutics is currently under evaluation in gross profit category among its peers.

Cardiol Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Cardiol Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cardiol Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Cardiol Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Cardiol Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease . Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Cardiol Therapeutics is traded on NASDAQ Exchange in the United States.

Cardiol Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Cardiol Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cardiol Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cardiol Therapeutics' important profitability drivers and their relationship over time.

Use Cardiol Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardiol Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Cardiol Therapeutics Pair Trading

Cardiol Therapeutics Class Pair Trading Analysis

The ability to find closely correlated positions to Agilent Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agilent Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agilent Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agilent Technologies to buy it.
The correlation of Agilent Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agilent Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agilent Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agilent Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Cardiol Therapeutics position

In addition to having Cardiol Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Large Growth Funds Thematic Idea Now

Large Growth Funds
Large Growth Funds Theme
Funds or Etfs that invest in stocks of large-sized companies with above-average risk and growth rate. The Large Growth Funds theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Growth Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Other Tools for Cardiol Stock

When running Cardiol Therapeutics' price analysis, check to measure Cardiol Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiol Therapeutics is operating at the current time. Most of Cardiol Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cardiol Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiol Therapeutics' price. Additionally, you may evaluate how the addition of Cardiol Therapeutics to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios